In the current study in the Pten+/− mouse model, we found that long‐term administration of rapamycin resulted in a highly significant extension of lifespan, accompanied by a delay in, but not full blockade of, the development of GI, thyroid, and endometrial tumours, with no impact on mammary and prostate cancer. The gene discussed is PTEN; the disease is prostate cancer.